jRCT1031250782招募中不适用
A prospective randomized controlled trial of remimazolam versus propofol on cerebral oxygenation during laminectomy in prone position under general anesthesia (PRO-REM Trial)
未提供0 个研究点目标入组 60 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 65age old over 至 No limit(—)
- 性别
- All
入选标准
- •Elderly patients over 65 years of age
- •Diagnosis: Patients with spinal disease at the thoracic and/or lumbar level requiring laminectomy, discectomy, and/or posterior spinal fusion
- •ASA classification: Patients classified as ASA I-III (including relatively healthy patients to patients with mild to moderate systemic disease)
- •BMI greater than or equal to 18 or less than or equal to 35
- •Able to tolerate prone position
- •Able to fully understand the study plan and provide informed consent on their own
- •Operating table: Spine surgery using a prone pillow, such as the Mizuno OSI Trios operating table or the Mizuno MOT-8300
排除标准
- •Uncontrolled cardiovascular disease (e.g., EF<30% heart failure, Af, other severe arrhythmias)
- •Severe respiratory disease (e.g., chronic obstructive pulmonary disease, high-risk obstructive sleep apnea (vital capacity <60%, volume <50%))
- •Severe hepatic impairment (e.g., Child-Pugh classification C)
- •Severe neurological disease (assessed by mini-cog test)
- •History of allergy to remimazolam, propofol, benzodiazepines, or soy/egg-based products
- •Angle-closure glaucoma
- •Emergency surgery
- •Spine surgery requiring head fixation with 3-point fixation
- •Refusal to participate in the study
研究者
相似试验
已完成
1 期
A trial to learn if different doses of REGN17092 are safe in healthy adults2023-505041-52-00Regeneron Pharmaceuticals Inc.128
招募中
1 期
A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT2024-519010-31-00Fondazione Melanoma Onlus80
尚未招募
4 期
Study of efficacy and side effects of imeglimin as an antidiabetic agent as single drug or as an add on drugCTRI/2024/04/065835Abhinav Garg200
招募中
2 期
Romiplostim in Inherited marrow failure syndromes - Safety and EfficacyCTRI/2024/03/063966INDIAN COUNCIL OF MEDICAL RESEARCH10
招募中
1 期
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.2025-522243-17-00Philogen S.p.A.96
